Febrile Neutropenia Market

Regular Patient Monitoring Reduces Stress on Clinicians amidst COVID-19 Outbreak

Patients with febrile neutropenia are at a high risk of contracting the coronavirus (COVID-19) infection. Hence, pharma companies in the febrile neutropenia market are increasing their production capabilities to manufacture intravenous (IV) antibiotics to avoid supply shocks in healthcare settings. Manufacturers are educating clinicians to conduct regular computed tomography (CT) scan of the chest of febrile neutropenia patients even in the absence of cough. This helps in early detection of COVID-19, and helps to effectively manage the symptoms at an early stage.

Moreover, cancer patients with neutropenia complications are susceptible to coronavirus. In order to tide over uncertainties stemming from the pandemic, companies in the febrile neutropenia market are increasing their focus in pediatric cancer patient care. Only patients with high risk or immediate risk are recommended with the granulocyte-colony stimulating factor (G-CSF) therapy to maintain stocks in healthcare facilities.

Collaborative Inter-professional Team Approach Helps Improve Medical Outcomes

The oral empiric therapy with a fluoroquinolone plus amoxicillin/clavulanate is considered as the gold standard in the treatment of low-risk febrile neutropenia patients. However, limitations in chemotherapy-induced neutropenia assessment tools such as the Clinical Index of Stable Febrile Neutropenia (CISNE) score model are hindering the growth of the febrile neutropenia market. Hence, pharma companies must collaborate with infectious disease specialists to improve medical outcomes in oncology emergency settings.

Manufacturers in the febrile neutropenia market should increase their R&D capabilities to develop improved formulations of IV antibiotics, as early admission of antibiotics has clinically helped to reduced mortality rates and minimize the time spent in hospitals. Pharmacists should work as a collaborative inter-professional team with clinicians to assist in antibiotic selection and dosing. There is a need for proper training of the nursing staff to monitor and report any changes taking place during the treatment.

Companies Collaborate with Multidisciplinary Research Teams to Decrease Occurrence of Infection

The treatment received by advanced cancer patients tends to weaken their immune systems and increases the risk of life-threatening infections such as febrile neutropenia. Hence, companies in the febrile neutropenia market are capitalizing on this opportunity to boost the availability of FDA (Food and Drug Administration)-approved drugs. However, lack of clear standard care pertaining to the patients and medicines has led to undetermined levels of risk. Hence, pharmaceutical manufacturers are collaborating with researchers at universities to determine the quality and safety of FDA-approved medications.

Companies are increasing efforts to gather data from over several thousands of cancer patients by setting up multidisciplinary research teams. This helps pharmaceutical manufacturers in the febrile neutropenia market to gain granular details into the rate of occurrence for the infection.

Artificial Intelligence Algorithms Give Rise to Personalized Infection Control Practices

Apart from FDA-approved medications, companies in the febrile neutropenia market are focusing on traditional measures such as the patient skincare, hand hygiene, central venous catheter care, and the likes to broaden their revenue streams. Manufacturers are innovating in products that deliver environmental protection, as febrile neutropenia patients are found to have a weak immune system. However, multidrug-resistant organisms (MDRO) are being reported in patients and is emerging as a challenge for pharmaceutical manufacturers. Hence, companies are using new technologies such as decolonization and the use of predictive models for the infection.

In addition, the proliferation of artificial intelligence (AI) algorithms has led to the trend of personalized infection control practices. Thus, companies in the febrile neutropenia market are gaining a strong research base in AI technologies to deliver better outcomes after IV antibiotics administration in patients.

Advancements in Biomarker Research Enable Efficacious Disease Monitoring in AML Patients

Febrile neutropenia in acute myeloid leukemia (AML) patients is considered as an oncologic emergency. In order to meet demanding needs of patients, manufacturers in the febrile neutropenia market are boosting their production outputs to increase accessibility to the empiric broad-spectrum antibiotic therapy. This therapy helps to prevent risks of sepsis and significantly reduces mortality rates. As such, MRDOs still pose as a challenge for AML patients with hematologic malignancies and neutropenic fever. Companies in the febrile neutropenia market are advancing in biomarker research to facilitate efficacious diagnosis and disease monitoring in AML patients.

Pharmaceutical manufacturers are increasing awareness about multiple risk stratification tools to determine the risk of adverse outcomes pertaining to neutropenic fever in patients. The empiric antibacterial therapy is being recommended for AML patients, since neutropenic fever necessitates prompt diagnostic evaluation. The AML-targeted therapy reduces potentially life-threatening side effects in patients.